Dismantling Cancer Cells’ Antioxidant Defenses: Phase I Trial of Mesothelioma Drug Shows Signs of Disease Control
RSO-021 targets PRX3 in mitochondria, exposing tumors to their own accumulated oxidative stress. In a small trial, 6 of 9 evaluable patients had disease control at 12 weeks, but whether it can extend survival remains to be confirmed in controlled studies.